search
Back to results

Effect of Folic Acid and Vitamin B12 Supplementation in Subjects With Type 2 Diabetes

Primary Purpose

Diabetes Mellitus, Type 2

Status
Completed
Phase
Phase 2
Locations
India
Study Type
Interventional
Intervention
Folic acid
Vitamin B12
Oral hypoglycemic agents [Metformin +/- Sulfonylurea]
Sponsored by
All India Institute of Medical Sciences, Bhubaneswar
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Diabetes Mellitus, Type 2

Eligibility Criteria

30 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Type 2 Diabetic patients within age group 30-65 years, on stable dose of anti-diabetic with/without anti-hypertensive drugs will be included in this study

Exclusion Criteria:

  • Subjects on non-allopathic forms of treatment for diabetic control.
  • Subjects with Chronic Renal disease and Liver disease.
  • Subjects with malabsorption.
  • Subjects with Thyroid function abnormalities.
  • HbA1c levels more than 10 %
  • Smoking
  • Alcoholism
  • Pregnant subjects
  • Subjects with vitamin B12 deficiency
  • Subjects already on Folate or Vitamin B12 supplementation due to some other medical condition
  • The detailed drug history of the subjects will be taken prior to including them in the study. Antibiotics like Fluoroquinolones; anti-seizure drugs like phenytoin; Corticosteroids and Hormonal Contraceptives; Hypolipidemic drugs like statins are known to affect Glucose metabolism and subjects on these medications will not be included in the study.

Sites / Locations

  • All India Institute of Medical Sciences, Bhubaneswar

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Experimental

Experimental

Experimental

Active Comparator

Arm Label

Folic acid

Vitamin B12

"Folic acid" and "Vitamin B12"

Control

Arm Description

Twenty type-2 diabetes patients with standard Oral hypoglycemic agents [Metformin +/- Sulfonylurea] will be recruited and additionally receive tab. Folic acid 5 mg once daily for 8 weeks

Twenty type-2 diabetes patients with standard Oral hypoglycemic agents [Metformin +/- Sulfonylurea] will be recruited and additionally receive tab. Vitamin B12 500 mcg once daily for 8 weeks

Twenty type-2 diabetes patients with standard Oral hypoglycemic agents [Metformin +/- Sulfonylurea] will be recruited and additionally receive both tab. Folic acid 5 mg once daily and tab. Vitamin B12 500 mcg once daily for 8 weeks

Twenty type-2 diabetes patients with standard Oral hypoglycemic agents [Metformin +/- Sulfonylurea] will be recruited and receive no additional supplementation

Outcomes

Primary Outcome Measures

HbA1c

Secondary Outcome Measures

Fasting plasma glucose
Fasting plasma insulin
Insulin Resistance
Using Homeostatic model assessment (HOMA2 calculator which uses fasting plasma glucose and plasma insulin values to calculate insulin resistance)
Serum total cholesterol
Serum triacylglycerol
Serum Low-density lipoprotein (LDL)
Serum High-density lipoprotein (HDL)
Serum Very Low-density lipoprotein (VLDL)
Serum Homocysteine
Serum Adiponectin
Serum Tumor Necrosis Factor (TNF)
Serum Interleukin-6 (IL-6)
Serum C reactive protein (CRP)

Full Information

First Posted
May 25, 2016
Last Updated
September 18, 2017
Sponsor
All India Institute of Medical Sciences, Bhubaneswar
search

1. Study Identification

Unique Protocol Identification Number
NCT02786823
Brief Title
Effect of Folic Acid and Vitamin B12 Supplementation in Subjects With Type 2 Diabetes
Official Title
Effect of Folic Acid and Vitamin B12 Supplementation on Biochemical Parameters in Subjects With Type-2 Diabetes
Study Type
Interventional

2. Study Status

Record Verification Date
September 2017
Overall Recruitment Status
Completed
Study Start Date
May 1, 2017 (Actual)
Primary Completion Date
August 15, 2017 (Actual)
Study Completion Date
September 15, 2017 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
All India Institute of Medical Sciences, Bhubaneswar

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This study aims to evaluate the effect of Folic acid and Vitamin B12 supplementation on Biochemical parameters in subjects with type-2 Diabetes. 80 selected subjects will be divided into 4 groups of 20 each. Group A: to receive Folic acid 5 mg once daily for 8 weeks along with standard oral anti-diabetic drugs; Group B: to receive Vitamin B12 500 mcg once daily for 8 weeks along with standard oral anti-diabetic drugs; Group C: to receive both Folic acid 5 mg once daily and Vitamin B12 500 mcg once daily for 8 weeks along with standard oral anti-diabetic drugs; Group D: to receive no additional intervention apart from standard oral anti-diabetic drugs. The biochemical parameters will be evaluated before and after the intervention.
Detailed Description
This is a randomized, parallel group, open label study to evaluate the effect of Folic acid and Vitamin B12 supplementation on Biochemical parameters in subjects with type-2 Diabetes. 80 selected subjects will be randomly assigned to 4 groups of 20 each as follows: Group A: to receive Folic acid 5 mg once daily for 8 weeks along with standard oral anti-diabetic drugs; Group B: to receive Vitamin B12 500 mcg once daily for 8 weeks along with standard oral anti-diabetic drugs; Group C: to receive both Folic acid 5 mg once daily and Vitamin B12 500 mcg once daily for 8 weeks along with standard oral anti-diabetic drugs; Group D: to receive no additional intervention apart from standard oral anti-diabetic drugs. The subjects will also be advised to be on a normal routine diet, not to skip any meal and not to change their exercise pattern (if any) during the study period.The compliance of the intervention will be monitored by instructing the patients to return all unused tablets at the end of the 8 weeks period of study. All the subjects will be asked to report after an overnight fasting of 12 hours on two occasions i.e. at the start of the study before allocation of group and 8 weeks after allocation. After measurement of body weight, height and blood pressure (by Mercury Sphygmomanometer), 5 milliliter of early morning fasting venous blood sample will be collected under aseptic measures on both the occasions. The samples collected will then be appropriately processed for the analysis of various biochemical parameters. The results of all the parameters evaluated will be recorded in the subject's Data Collection Form.The data will be analyzed using Statistical Package for the Social Sciences (SPSS) version 21.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes Mellitus, Type 2

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2, Phase 3
Interventional Study Model
Factorial Assignment
Masking
Care ProviderOutcomes Assessor
Allocation
Randomized
Enrollment
80 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Folic acid
Arm Type
Experimental
Arm Description
Twenty type-2 diabetes patients with standard Oral hypoglycemic agents [Metformin +/- Sulfonylurea] will be recruited and additionally receive tab. Folic acid 5 mg once daily for 8 weeks
Arm Title
Vitamin B12
Arm Type
Experimental
Arm Description
Twenty type-2 diabetes patients with standard Oral hypoglycemic agents [Metformin +/- Sulfonylurea] will be recruited and additionally receive tab. Vitamin B12 500 mcg once daily for 8 weeks
Arm Title
"Folic acid" and "Vitamin B12"
Arm Type
Experimental
Arm Description
Twenty type-2 diabetes patients with standard Oral hypoglycemic agents [Metformin +/- Sulfonylurea] will be recruited and additionally receive both tab. Folic acid 5 mg once daily and tab. Vitamin B12 500 mcg once daily for 8 weeks
Arm Title
Control
Arm Type
Active Comparator
Arm Description
Twenty type-2 diabetes patients with standard Oral hypoglycemic agents [Metformin +/- Sulfonylurea] will be recruited and receive no additional supplementation
Intervention Type
Dietary Supplement
Intervention Name(s)
Folic acid
Intervention Description
tab. Folic acid 5 mg
Intervention Type
Dietary Supplement
Intervention Name(s)
Vitamin B12
Intervention Description
tab. Vitamin B12 500 mcg
Intervention Type
Drug
Intervention Name(s)
Oral hypoglycemic agents [Metformin +/- Sulfonylurea]
Other Intervention Name(s)
Metformin, Sulfonylurea
Intervention Description
Patients receiving either of the following oral hypoglycemic agents Sulfonylurea Metformin Metformin plus Sulfonylurea
Primary Outcome Measure Information:
Title
HbA1c
Time Frame
8 weeks
Secondary Outcome Measure Information:
Title
Fasting plasma glucose
Time Frame
8 weeks
Title
Fasting plasma insulin
Time Frame
8 weeks
Title
Insulin Resistance
Description
Using Homeostatic model assessment (HOMA2 calculator which uses fasting plasma glucose and plasma insulin values to calculate insulin resistance)
Time Frame
8 weeks
Title
Serum total cholesterol
Time Frame
8 weeks
Title
Serum triacylglycerol
Time Frame
8 weeks
Title
Serum Low-density lipoprotein (LDL)
Time Frame
8 weeks
Title
Serum High-density lipoprotein (HDL)
Time Frame
8 weeks
Title
Serum Very Low-density lipoprotein (VLDL)
Time Frame
8 weeks
Title
Serum Homocysteine
Time Frame
8 weeks
Title
Serum Adiponectin
Time Frame
8 weeks
Title
Serum Tumor Necrosis Factor (TNF)
Time Frame
8 weeks
Title
Serum Interleukin-6 (IL-6)
Time Frame
8 weeks
Title
Serum C reactive protein (CRP)
Time Frame
8 weeks

10. Eligibility

Sex
All
Minimum Age & Unit of Time
30 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Type 2 Diabetic patients within age group 30-65 years, on stable dose of anti-diabetic with/without anti-hypertensive drugs will be included in this study Exclusion Criteria: Subjects on non-allopathic forms of treatment for diabetic control. Subjects with Chronic Renal disease and Liver disease. Subjects with malabsorption. Subjects with Thyroid function abnormalities. HbA1c levels more than 10 % Smoking Alcoholism Pregnant subjects Subjects with vitamin B12 deficiency Subjects already on Folate or Vitamin B12 supplementation due to some other medical condition The detailed drug history of the subjects will be taken prior to including them in the study. Antibiotics like Fluoroquinolones; anti-seizure drugs like phenytoin; Corticosteroids and Hormonal Contraceptives; Hypolipidemic drugs like statins are known to affect Glucose metabolism and subjects on these medications will not be included in the study.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Debapriya Bandyopadhyay, M.D.
Organizational Affiliation
All India Institute of Medical Sciences, Bhubaneswar
Official's Role
Principal Investigator
Facility Information:
Facility Name
All India Institute of Medical Sciences, Bhubaneswar
City
Bhubaneswar
State/Province
Odisha
ZIP/Postal Code
751019
Country
India

12. IPD Sharing Statement

Learn more about this trial

Effect of Folic Acid and Vitamin B12 Supplementation in Subjects With Type 2 Diabetes

We'll reach out to this number within 24 hrs